Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Oct;30(10):1027.e1-1027.e14.
doi: 10.1016/j.jtct.2024.07.009. Epub 2024 Jul 20.

Impact of Race and Ethnicity on Outcomes After Umbilical Cord Blood Transplantation

Affiliations

Impact of Race and Ethnicity on Outcomes After Umbilical Cord Blood Transplantation

Karen Ballen et al. Transplant Cell Ther. 2024 Oct.

Abstract

Background: Umbilical cord blood transplant (UCBT) improves access to transplant for patients lacking a fully matched donor. Previous Center for International Blood and Marrow Transplant Research (CIBMTR) showed that Black patients had a lower overall survival (OS) than White patients following single UCBT. The current study draws on a larger modern cohort and compares outcomes among White, Latinx, Black, and Asian patients.

Objective: To compare outcomes by social determinants of health.

Study design: We designed a retrospective study using CIBMTR data. US patients were between ages 1 and 80; 983 received single and 1529 double UCBT as reported to CIBMTR, following either a myeloablative (N = 1752) or reduced intensity conditioning (N = 759) for acute myeloid leukemia, acute lymphoid leukemia, or myelodysplasia. The primary outcome was 2-year OS. Secondary outcomes included disease free survival, transplant related mortality (TRM), acute and chronic graft vs host disease (GVHD), and GVHD free, relapse free survival (GRFS).

Results: For 1705 adults, in univariate analysis, 2-year OS was 41.5% (99% CI, 37.6 to 45.3) for Whites, 36.1% (99% CI, 28.2 to 44.5) for Latinx, 45.8% (99% CI, 36.7 to 55.1) for Blacks, and 44.5% (99% CI, 33.6 to 55.6) for Asians. In multivariate analysis of adults, Latinx patients had inferior OS compared to black patients (p = .0005, HR 1.45, 99% CI 1.18 to 1.79). OS improved over time for all racial/ethnic groups. GVHD rates were comparable among the different racial/ethnic groups. In the 807 children, the 2-year OS in univariate analysis was 66.1% (99% CI, 59.7 to 72.2) for Whites, 57.1% (99%CI, 49 to 64.9) for Latinx, 46.8% (99%CI, 35.3 to 58.4) for Blacks, and 53.8% (99%CI, 32.7 to 74.2) for Asians. In multivariate analysis, no difference in OS was observed among racial/ethnic groups (p = .051). Grade III/IV acute GVHD was higher in Blacks compared with Whites (p = .0016, HR 2.25, 99% CI 1.36 to 3.74) and Latinx (p = .0016, HR 2.17, 99% CI 1.43 to 3.30). There was no survival advantage to receiving a UCB unit from a donor of similar race and ethnicity, for any racial/ethnic groups, for both children and adults. Black and Latinx adult patients were more likely to live in areas defined as high poverty. Patients from high poverty level areas had worse OS (p = .03), due to a higher rate of TRM (p=0.04). Educational level, and type of insurance did not impact overall survival, GVHD, TRM or other transplant outcomes. Children from areas with a higher poverty level had higher TRM, regardless of race and ethnicity (p = .02). Public health insurance, such as Medicaid, was also associated with a higher TRM (p = .02). However, poverty did not impact pediatric OS, DFS, or other post-transplant outcomes.

Conclusions: OS for UCBT has improved over time. In adults, OS is comparable among Whites, Blacks, and Asians and lower for Latinx patients. In children, OS is comparable among Whites, Blacks, Latinx, and Asians, but Grade III/IV acute GVHD was higher in Black patients. There was no survival benefit to matching UCB unit and patient by race and ethnicity for adults and children.

Keywords: Cord Blood; Ethnicity; Race; Stem cell transplant.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Statement: Dr. Ballen reports research funding (to her institution) from Stem-Line. Dr. Frangoul reports consulting with Vertex Pharmaceutical, Editas Medicine and speaker bureau with Jazz Pharmaceuticals. Dr. Savani reports government COI. Dr. Sharma has received consultant fee from Spotlight Therapeutics, Medexus Inc., Vertex Pharmaceuticals, Sangamo Therapeutics and Editas Medicine. He is a medical monitor for RCI BMT CSIDE clinical trial for which receives financial compensation. He has also received research funding from CRISPR Therapeutics and honoraria from Vindico Medical Education. Dr. Sharma is the St. Jude Children’s Research Hospital site principal investigator of clinical trials for genome editing of sickle cell disease sponsored by Vertex Pharmaceuticals/CRISPR Therapeutics (NCT03745287), Novartis Pharmaceuticals (NCT04443907) and Beam Therapeutics (NCT05456880). The industry sponsors provide funding for the clinical trial, which includes salary support paid to Dr. Sharma’s institution. Dr. Sharma has no direct financial interest in these therapies. Dr. Rangarajan reports Medical Monitoring for CD33 CAR T (honorary: no fees). Dr. Kindwall-Keller reports DSMB for OrcaBio. Dr. Gergis reports consulting fees from Gamida Cell. Dr. Farhadfar reports compensation from the advisory board for Incyte. Dr. Wood reports research funding (to their institution) by Genentech, Pfizer; consulting (compensation) from Teladoc; advising for Quantum Health and Koneksa Health; and receives salary support from the American Society of Hematology Research Collaborative. Dr. Hashmi reports compensation from advisory boards in Asia for GVHD and BMT drugs; and gives talks on educational CME programs which are sponsored by pharma that are never on commercial drug promotions.

Figures

Figure 1.
Figure 1.
Overall survival by race/ethnicity for adult and pediatric patients receiving umbilical cord blood transplant.
Figure 2.
Figure 2.
Improvement in Outcomes overtime for adult patients receiving umbilical cord blood transplant.
Figure 3.
Figure 3.
Overall Survival by HLA match for adults (3A) and pediatrics (3 B).
Figure 4.
Figure 4.
Overall survival by race/ethnicity matching of patient and cord blood unit for adults.

References

    1. Ballen KK, Gluckman E, Broxmeyer HE. Umbilical cord blood transplantation the first 25 years and beyond. Blood. 2013;122(4):491–498. - PMC - PubMed
    1. Wagner JE, Ballen KK, Zhang MJ, et al. Comparison of haploidentical and umbilical cord blood transplantation after myeloablative conditioning. Blood Advances. 2021;5(20):4064–4072. - PMC - PubMed
    1. Brunstein CG, Fuchs EL, Carter SL, et al. Alternative donor transplantation: results of parallel Phase II trials using HLA-mismatched related bone marrow or unrelated umbilical cord blood grafts. Blood. 2011;118:282–288. - PMC - PubMed
    1. Eapen M, Rocha V, Sanz G, et al. Effect of graft source on unrelated donor hematopoietic stem cell transplantation in adults with acute leukemia. Lancet Oncol. 2010;11:653–660. - PMC - PubMed
    1. Marks DI, Woo KA, Zhong X, et al. Unrelated umbilical cord blood transplant for adult acute lymphoblastic leukemia in first and second complete remission: a comparison with allografts from adult unrelated donors. Haematologica. 2014;99(2):322–328. - PMC - PubMed

Publication types

MeSH terms

LinkOut - more resources